Logo Cognitive Behavior Therapy (LCBT) Digital Application for Reducing Anxiety in Hemodialysis Patients at RSUD Prembun in May 2024: A Pilot Study

Abstract

Background: Hemodialysis patients face significant anxiety due to the chronic nature of kidney disease and the stress of frequent treatments. The repeated hospital visits, invasiveness of the procedure, and uncertainty about prognosis contribute to elevated anxiety levels, which can impair overall quality of life and clinical outcomes. Anxiety can also hinder treatment adherence, leading to poorer health outcomes and complicating disease management.
Objective: This study evaluates the feasibility and preliminary efficacy of a Logo Cognitive Behavior Therapy (LCBT) digital application for reducing anxiety among hemodialysis patients at RSUD Prembun.
Methods: In this randomized controlled pilot trial, 30 hemodialysis patients were divided into LCBT (n=15) and control (n=15) groups. The LCBT group used the application for 30 minutes daily over eight weeks. Anxiety levels were measured using the Hamilton Anxiety Rating Scale (HARS) before and after the intervention. Statistical analysis involved paired t-tests and independent t-tests.
Results: The LCBT group exhibited a significant reduction in anxiety (mean score decreased from 20.3 ± 4.2 to 10.1 ± 3.4) compared to the control group (reduction from 19.7 ± 4.1 to 15.8 ± 4.2) (p < 0.01). Improvements were noted across all anxiety subscales.
Conclusion: The LCBT digital application effectively reduces anxiety in hemodialysis patients. Further research with larger samples and extended follow-up is needed to confirm these findings.